SH

Steve L. Hoerter

Board Member at Oric Pharmaceuticals

Mr. Hoerter has served as a member of the board of directors since August 2021. Mr. Hoerter currently serves as President and Chief Executive Officer of Deciphera Pharmaceuticals, a position he has held since March 2018. Prior to joining Deciphera, Mr. Hoerter served as the Chief Commercial Officer of Agios Pharmaceuticals from 2016 to 2019. From 2011 to 2015, Mr. Hoerter served as Senior Vice President, Commercial and from 2015 to 2016, as Executive Vice President and Chief Commercial Officer at Clovis Oncology.

Previously, he was General Manager and Management Center Head at Roche Group for the Sub-Saharan Africa and Indian Ocean Region. From 2005 to 2010, Mr. Hoerter held a variety of positions at Genentech, including serving on the senior leadership team for Genentech's bio-oncology business. Prior to joining Genentech, Mr. Hoerter held commercial roles at Chiron Corporation and Eli Lilly and Company in the United States, Europe and Africa. Mr. Hoerter has served on the board of directors of Deciphera since May 2018 and previously served on the board of directors of Constellation Pharmaceuticals, from September 2018 through its acquisition by MorphoSys AG in July 2021, and Ignyta from December 2016 through its acquisition by Roche Holding AG in February 2018. Mr. Hoerter holds a B.A. from Bucknell University, an M.B.A. from Tilburg University, and an M.S. in management from Purdue University.


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


Oric Pharmaceuticals

ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.